Clinical trials: TPF
Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
This is a phase II study of preoperative chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced resectable oral cavity squamous cell cancer.
- Trial name
- NCT01914900
- Testing
- docetaxel, cisplatin, 5 fluorouracil
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Larynx Cancer
Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer
Treatment of patients with one cycle of induction chemotherapy to select for organ preservation of the larynx has been proven as a standard approach. When compared to historical controls.
- Trial name
- NCT01073683
- Testing
- laryngoscopy, Taxotere (Docetaxel), Cisplatin, 5FU
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rabin Medical Center
Nasopharyngeal Carcinoma
By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC
This study is aimed to investigate the short-term efficacy and toxicities of local advanced nasopharyngeal carcinoma (NPC) treated with TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy and…
- Trial name
- NCT03557112
- Testing
- Nimotuzumab, Cisplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Guiyang Medical University
Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck
InductionChemo-Radio-Antibody-Treatment
This is an open-label, randomized, Phase II-study to evaluate the efficacy of a standard-TPF induction chemotherapy (IC) and an alternative TPF induction chemotherapy followed by radio-antibody-therapy, in patients with…
- Trial name
- ICRAT (NCT01181401)
- Testing
- TPF induction chemotherapy, TPF experimental, Standard Radiochemotherapy (HART)
- Where
- 5 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Charite University, Berlin, Germany
Neoplasm Neck
Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC
To investigate the predictive value of stathmin expression as a predictive biomarker in OSCC patients, who treated with TPF (docetaxel, cisplatin and 5-fluorouracil ) induction chemotherapy followed by radical surgery and…
- Trial name
- NCT03326947
- Testing
- docetaxel, cisplatin and 5-fluorouracil
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma
Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)
The DeLOS II trial is a multicenter randomised phase II trial investigating a TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by laryngectomy operable carcinoma of the larynx/hypopharynx.
- Trial name
- DeLOS II (NCT00508664)
- Testing
- Radiation, Cetuximab, Docetaxel
- Where
- 27 sites in Austria, Germany
- Volunteers
- 180 people
- Sponsor
- ClinAssess
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)
The primary objective of this study is to determine the response rate, tolerance and overall survival in patients with stage III, IVa, IVb NPC treated with neoadjuvant chemotherapy (TPF regimen) and concurrent chemoradiation.
- Trial name
- TPF for NPC (NCT00817583)
- Testing
- docetaxel, cisplatin, fluorouracil, 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Oropharynx Cancer, Squamous Cell Carcinoma of the Oral Cavity
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in patients with resectable oropharyngeal and cavity of the mouth cancer.
- Trial name
- NCT01108042
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
- Where
- 4 sites in Germany
- Volunteers
- 71 people
- Sponsor
- Orlando Guntinas-Lichius, Prof. Dr. med.
Head and Neck Neoplasms
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell…
- Trial name
- NCT00402545
- Testing
- Cetuximab, Docetaxel, Cisplatin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
The goal of this clinical research study is to learn which chemotherapy combination is more effective in treating locally advanced head and neck squamous cell carcinoma. The side effects of these combinations will also be studied.
- Trial name
- NCT01154920
- Testing
- Paclitaxel, Carboplatin, Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer
1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced…
- Trial name
- NCT00273546
- Testing
- XRP6976 (Docetaxel/Taxotere)
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 500 people
- Sponsor
- Sanofi
Carcinoma, Squamous Cell, Mouth Neoplasms
Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers
The purpose of this study is to determine if there is a correlation between tumor response after 3 doses of chemotherapy by induction using Docetaxel, Cisplatine and 5-Fluorouracile for advanced stage epidermoid carcinomas of the…
- Conditions
- Carcinoma, Squamous Cell, Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms
- Trial name
- APPROCHE ORL (NCT01104714)
- Where
- 14 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Head and Neck Squamous Cell Carcinoma
Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma
Nimotuzumab (hR3) is an humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01425736
- Testing
- Chemotherapy, Nimotuzumab and Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 91 people
- Sponsor
- Wei Guo
Esophageal Squamous Cell Carcinoma
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if immune microenvironment modification could improve the effect of chemoradiotherapy for patients with local advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06401447
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer.
- Trial name
- NCT01221753
- Testing
- docetaxel, cisplatin, 5-FU
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Head and Neck Carcinoma
Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck
This study aimed to assess the efficacy and safety for biweekly TPF as induction chemotherapy for locally advanced head and neck cancer
- Trial name
- NCT04397341
- Testing
- docetaxel, cisplatin, fluorouracil
- Volunteers
- 58 people
- Sponsor
- China Medical University Hospital
Head and Neck Cancer
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00095875
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 15 sites in United States, Germany
- Volunteers
- 145 people
- Sponsor
- Dana-Farber Cancer Institute
Mouth Neoplasms, Carcinoma, Squamous Cell
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
To confirm the subgroup result from TPF (docetaxel, cisplatin and 5-fluorouracil ) trial (NCT01542931) that cN2 OSCC patients could benefit from TPF induction chemotherapy compared to the standard treatment.
- Trial name
- NCT02285543
- Testing
- TPF induction chemotherapy, surgery, radiotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Patients With Head and Neck Cancer (ORL)
Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy
Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) is a mainstay for treating head and neck cancers, but elderly or fragile patients are often precluded because of the risk of severe toxicities associated with this protocol.
- Trial name
- 5-FU (NCT02484677)
- Testing
- Cisplatin, Docetaxel, 5-Fluorouracile
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Head and Neck Neoplasms
Docetaxel in Head and Neck Cancer
Primary Objective: Phase II: To determine the best treatment scheme (TPF vs. PF). Phase III: To compare the time to progression and the treatment failure at the 3 arms. Secondary objectives: To evaluate the safety at the 3 arms.
- Trial name
- NCT00261703
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin + radiotherapy
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 439 people
- Sponsor
- Sanofi